KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24
Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее
CAR T Options in MyelomaПодробнее
Racial and Ethnic Differences in Clinical Outcomes Among Myeloma Pts Treated with CAR T TherapyПодробнее
CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее
Immune Profiling and Cellular Therapies | Bruno Paiva, PHD | IMS 2023Подробнее
The potentially curative role of CAR-T therapy in myelomaПодробнее
What is CAR T-cell therapy and how does it work?Подробнее
The management & optimization of CAR T-cell therapy in myelomaПодробнее
Clinical Trial: BCMA CAR T Cell Trial with Adam Cohen, MD, University PennsylvaniaПодробнее
The value of CAR-T cell therapy for the treatment of R/R multiple myelomaПодробнее
Current and Emerging CAR T-Cell Therapies for MyelomaПодробнее
CAR T-Cell Therapies | High Impact Topic (HIT)Подробнее
Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023Подробнее
A novel CAR-T cell therapy targeting BCMA is highly effective for pts with relapsed multiple myelomaПодробнее
Dr. Bruno Paiva on Multiple MyelomaПодробнее
CAR T-cells in myeloma: patients’ perspectiveПодробнее
Novel allo-CART therapies and their role in the treatment of hematological malignanciesПодробнее
